Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
PA Watson, VK Arora, CL Sawyers - Nature Reviews Cancer, 2015 - nature.com
During the past 10 years, preclinical studies implicating sustained androgen receptor (AR)
signalling as the primary driver of castration-resistant prostate cancer (CRPC) have led to …
signalling as the primary driver of castration-resistant prostate cancer (CRPC) have led to …
Androgen signaling in prostate cancer
The androgen-signaling axis plays a pivotal role in the pathogenesis of prostate cancer.
Since the landmark discovery by Huggins and Hodges, gonadal depletion of androgens has …
Since the landmark discovery by Huggins and Hodges, gonadal depletion of androgens has …
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
BACKGROUND. Liquid biopsies have demonstrated that the constitutively active androgen
receptor splice variant-7 (AR-V7) associates with reduced response and overall survival …
receptor splice variant-7 (AR-V7) associates with reduced response and overall survival …
Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines
Persistent androgen receptor (AR) transcriptional activity underlies resistance to AR-
targeted therapy and progression to lethal castration-resistant prostate cancer (CRPC) …
targeted therapy and progression to lethal castration-resistant prostate cancer (CRPC) …
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer
R Hu, C Lu, EA Mostaghel, S Yegnasubramanian… - Cancer research, 2012 - AACR
Continued androgen receptor (AR) signaling is an established mechanism underlying
castration-resistant prostate cancer (CRPC), and suppression of androgen receptor …
castration-resistant prostate cancer (CRPC), and suppression of androgen receptor …
Second generation androgen receptor antagonists and challenges in prostate cancer treatment
Y Chen, Q Zhou, W Hankey, X Fang, F Yuan - Cell Death & Disease, 2022 - nature.com
Prostate cancer is a hormone-dependent malignancy, whose onset and progression are
closely related to the activity of the androgen receptor (AR) signaling pathway. Due to this …
closely related to the activity of the androgen receptor (AR) signaling pathway. Due to this …
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
AA Shafi, AE Yen, NL Weigel - Pharmacology & therapeutics, 2013 - Elsevier
Abstract In the United States, prostate cancer (PCa) is the most commonly diagnosed non-
cutaneous cancer in males and the second leading cause of cancer-related death for men …
cutaneous cancer in males and the second leading cause of cancer-related death for men …
Application of prostate cancer models for preclinical study: advantages and limitations of cell lines, patient-derived xenografts, and three-dimensional culture of patient …
T Namekawa, K Ikeda, K Horie-Inoue, S Inoue - Cells, 2019 - mdpi.com
Various preclinical models have been developed to clarify the pathophysiology of prostate
cancer (PCa). Traditional PCa cell lines from clinical metastatic lesions, as exemplified by …
cancer (PCa). Traditional PCa cell lines from clinical metastatic lesions, as exemplified by …
[HTML][HTML] Alternatively spliced androgen receptor variants
SM Dehm, DJ Tindall - Endocrine-related cancer, 2011 - erc.bioscientifica.com
Alternative splicing is an important mechanism for increasing functional diversity from a
limited set of genes. Deregulation of this process is common in diverse pathologic …
limited set of genes. Deregulation of this process is common in diverse pathologic …
The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer …
Background The androgen receptor splice variant 7 (AR-V7) is associated with resistance to
hormonal therapy in castration-resistant prostate cancer (CRPC). Due to limitations of the …
hormonal therapy in castration-resistant prostate cancer (CRPC). Due to limitations of the …